1. Home
  2. INHD vs AKTX Comparison

INHD vs AKTX Comparison

Compare INHD & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inno Holdings Inc.

INHD

Inno Holdings Inc.

HOLD

Current Price

$1.12

Market Cap

9.6M

Sector

N/A

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.26

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INHD
AKTX
Founded
2019
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
9.1M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
INHD
AKTX
Price
$1.12
$0.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
268.0K
198.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
17.61
N/A
EPS
N/A
N/A
Revenue
$2,846,250.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
221.43
N/A
52 Week Low
$0.06
$0.22
52 Week High
$15.90
$1.72

Technical Indicators

Market Signals
Indicator
INHD
AKTX
Relative Strength Index (RSI) 48.81 51.89
Support Level $1.04 $0.25
Resistance Level $1.17 $0.27
Average True Range (ATR) 0.09 0.03
MACD -0.01 0.01
Stochastic Oscillator 49.92 72.22

Price Performance

Historical Comparison
INHD
AKTX

About INHD Inno Holdings Inc.

Inno Holdings Inc is a building technology company with a mission to transform the construction industry with its proprietary cold-formed steel-framing technology and other innovations. It is a manufacturer of cold-formed-steel members and prefabricated homes. It offers a full range of services required to transform raw materials into precise steel framing products and prefabricated homes. The company sells these finished products either to businesses or directly to customers. The finished products and cold-formed-steel members are used in a variety of building types, including residential, commercial, industrial and infrastructure.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: